EP2976101

GLAXOSMITHKLINE BIOLOGICALS S.A.
Application Number
EP14711232A
Filing Date
Mar 17, 2014
Status
Revoked
Feb 2, 2024
Grant Date
Aug 19, 2020
External Links
Slate, Register

Biblio Summary

The patent EP2976101B1 was granted on Aug 19, 2020 by Glaxosmithkline Biologicals S.A. The patent is currently Revoked.

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SANOFI PASTEURMay 18, 2021ADMISSIBLE

The table below shows the patents of Glaxosmithkline Biologicals S.A. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3480209Expression SystemNov 29, 20231
EP4043040Small Liposomes For Delivery Of Immunogen-Encoding RnaJan 11, 20234
EP4008357Small Liposomes For Delivery Of Immunogen-Encoding RnaDec 28, 20224

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.